Concentration of Credit Risk and Significant Customers

9 Months Ended

Sep. 30, 2012

Concentration of Credit Risk and Significant Customers [Abstract]

Concentration of Credit Risk and Significant Customers

Note 2 - Concentration of Credit Risk and Significant Customers

We operate in an industry that is highly regulated, competitive and rapidly changing and involves numerous risks and uncertainties. Significant technological and/or regulatory changes, the emergence of competitive products and other factors could negatively impact our consolidated financial position or results of operations.

We have been dependent on our collaborative agreements with a limited number of third parties for a substantial portion of our revenue, and our discovery and development activities may be delayed or reduced if we do not maintain successful collaborative arrangements. We had revenue from customers, as a percentage of total revenue, as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2012			2011			2012
Novartis		-			95	%		-			36	%
Monsanto		-			5	%					54	%
Mirna		-			-			-			4	%
Debiopharm		91	%		-			63	%		1	%
Astra Zeneca		-			-			9	%		-
Undisclosed Partner #1		-			-			8	%		-
Other		9	%		-			20	%		5	%
Total		100	%		100	%		100	%		100	%